Outlook Therapeutics says FDA approves LYTENAVA for wet AMD
OTLK•Launch and exclusivity outlook
The company expects about 12 years of US market exclusivity under the BPCIA.
Launch preparations are underway, with US availability targeted before year-end.
FDA approves LYTENAVA for wet AMD
Outlook Therapeutics says the FDA has approved LYTENAVA (bevacizumab-vikg) to treat wet age-related macular degeneration.
The decision makes LYTENAVA the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the US.
